Member Info for Timster

Good news is only another 4p and another Hurstbot trading prediction becomes true.... Forget the sealion......

Don't make it about the boring twunt again, literally noone (well maybe two fans) cares what it says, it's essays are boring, it's credibility is zero.

I'm interested in what BITL asked star right, do you think this is a bit more than retail now, volume over the last few weeks has been impressive

The numis professional analyst doesn't seem that special

Interesting use of the magic calculator. But did you mean 0.45%

If(conversation $true){$Respond=$NULL}

Else{$Respond = GenrateCrapFunction

$Respond}

Many thanks, I answer only to sujood

He said Q4, it's still Q4.

Q4

October ❌

November ❔

December ❔

Can't wait till the 21st, well done Andy...

Quickly gains, 2% whoosh

.

Jadams spike warning required, people thank him you know....

Quick in medical approval terms will never equate to what the average person regards quick as 😀

Sneaky

@matml74

https://www.voxmarkets.co.uk/media/6509b4b551756d4ab6acdf9a/

7 mins in, short study at US sites.

Sure he said it in a Q&A somewhere too, but I can't find it.

I agree and *I think* he stated phase 2 will be US only (could have imagined that).

The 2 week study is definitely only US

Amazing, same as last week then 👍

What are you saying? Avacta are a month too late? Or you are, to submit your views?

I would imagine that in conjunction with talking to the FDA avacta are also in contact with the MHRA, it was them who approved the extended cohorts at much higher dosage than originally planned.

They've obviously taken the decision though that a total change in 1b will get through approvals much quicker in the US than it would in the UK.

SP holding well, what's happened to the death spiral after the HCI share issue.

Good posts yesterday around the FDA approval process.

Q4 could be very eventful we should have (almost definitely)

-P1a data to date

Then

-cohort 7 completion, imo can't see them finding an MTD

-two weekly dosing study approval and commencement in the US. From the last RNS this will be first line treatment for STS.

There are also a load of other possibilities for news, but those 3 are the most likely short term.

Never been wrong Bella, apart from always.

Predicting an RNS in November is a mystical miracle which no one could forsee .....